Clinical trials: Pneumococcal Infections
Pneumococcal Disease
A Study to Learn About the Safety of an Expanded Pneumococcal Vaccine in Healthy Infants
The purpose of this study is to learn about the safety of a new pneumococcal vaccine and how the new pneumococcal vaccine helps to fight against germs that can cause pneumonia (lung infections), meningitis (brain infections), and…
- Trial name
- NCT07573462
- Testing
- PG4, 20-valent pneumococcal conjugate vaccine (20vPnC)
- Where
- 78 sites in United States, Argentina and 8 more
- Volunteers
- 2,400 people, healthy volunteers welcome
- Sponsor
- Pfizer
Pneumococcal Disease
Study to Learn About Safety, Tolerability, and Immune Response of a Catch-up Pneumococcal Vaccine in Children and Adolescents
The purpose of this study is to learn about the safety of a new pneumococcal vaccine and how the new pneumococcal vaccine helps to fight against germs that can cause pneumonia (lung infections), meningitis (brain infections), and…
- Trial name
- NCT07660198
- Testing
- PG4, 20-valent pneumococcal conjugate vaccine (20vPnC)
- Where
- 77 sites in United States, Finland and 2 more
- Volunteers
- 1,200 people, healthy volunteers welcome
- Sponsor
- Pfizer
Pneumococcal Disease
A Study to Understand the Safety of the 20vPnC Vaccine in Healthy Chinese Adults, Children, and Infant
The purpose of this study is to learn about the safety of the 20-valent pneumococcal conjugate vaccine (20vPnC) among adults, children, and infants, as well as the immunogenicity of 20vPnC among infants and children under 2 years…
- Trial name
- NCT07023081
- Testing
- 20vPnC, 13vPnC
- Where
- 2 sites in China
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Pfizer
Pneumococcal Infections, Immunization Programs
Randomized Controlled Trial Of Text Messages To Increase Pneumococcal Vaccination In Adults In Chile.
The goal of this randomized controlled trial is to learn if text message reminders sent through WhatsApp increase pneumococcal vaccination coverage in adults turning 65 years old in Chile.
- Conditions
- Pneumococcal Infections, Immunization Programs, Vaccination Coverage, Text Messaging (Intervention)
- Trial name
- PNEUMO-SMS (NCT07659470)
- Testing
- WhatsApp text message reminder for pneumococcal vaccination
- Where
- Chile
- Volunteers
- 40,753 people, healthy volunteers welcome
- Sponsor
- Pablo Tomás Valenzuela García
Pneumococcal Disease
A Study to Learn About How a New Pneumococcal Vaccine Works in Infants.
The purpose of this study is to learn about the safety of a new pneumococcal vaccine and how the new pneumococcal vaccine helps to fight against germs that can cause pneumonia (lung infections), meningitis (brain infections), and…
- Trial name
- NCT07629440
- Testing
- PG4, 20-valent pneumococcal conjugate vaccine (20vPnC)
- Where
- 130 sites in United States, Japan and 1 more
- Volunteers
- 3,230 people, healthy volunteers welcome
- Sponsor
- Pfizer
Pneumococcal Disease
A Study to Learn About How a New Pneumococcal Vaccine Works in Infants
The purpose of this study is to learn about the safety of a new pneumococcal vaccine and how the new pneumococcal vaccine helps to fight against germs in infants when compared to the pneumococcal vaccines that are currently in…
- Trial name
- NCT06524414
- Testing
- PG4, 20-valent pneumococcal conjugate vaccine (20vPnC), 15-valent pneumococcal conjugate vaccine (PCV15)
- Where
- 67 sites in United States, Puerto Rico
- Volunteers
- 605 people, healthy volunteers welcome
- Sponsor
- Pfizer
Pneumococcal Disease
Safety, Tolerability, and Immunogenicity of VAX-31 in Adults ≥50 Years With Immunobridging to Adults 18-49
The primary objectives of this study are to evaluate the safety, tolerability, immunologic noninferiority (for shared serotypes) and immunologic superiority (for novel serotypes) of VAX-31 compared to PCV21 and PCV20 in adults…
- Trial name
- NCT07284654
- Testing
- 31 valent pneumococcal conjugate vaccine, PCV20, PCV21
- Where
- 30 sites in United States
- Volunteers
- 4,049 people, healthy volunteers welcome
- Sponsor
- Vaxcyte, Inc.
Pneumococcal Disease
A Study to Assess the Safety, Tolerability, and Immunogenicity of 3 Lots of a Multivalent Pneumococcal Conjugate Vaccine Administered to Adults
The purpose of this study is to provide safety data and demonstrate lot consistency with the PG4 vaccine by evaluating the immunogenicity of 3 different lots of this vaccine.
- Trial name
- NCT07794748
- Testing
- PG4 Multivalent Vaccine, 20 Valent Pneumococcal Conjugate Vaccine (20vPnC)
- Where
- 37 sites in United States
- Volunteers
- 4,670 people, healthy volunteers welcome
- Sponsor
- Pfizer
Pneumonia, Bacterial, Pneumococcal Infections
A Phase 2 Study to Evaluate the Safety, Tolerability, and Immune Response of AFX3772 Vaccine in Healthy Infants
This is a Phase 2 clinical study evaluating AFX3772 in healthy infants for the prevention of pneumococcal disease. The purpose of this study is to determine the safety, tolerability, and immunogenicity of three different…
- Conditions
- Pneumonia, Bacterial, Pneumococcal Infections, Pneumonia, Pneumococcal
- Trial name
- NCT05412030
- Testing
- AFX3772, Prevnar 13, Prevnar 20
- Where
- 52 sites in United States, Puerto Rico
- Volunteers
- 388 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Pneumococcal Immunization, Healthy Volunteers
Lot-to-lot Consistency Study of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From 2 Months of Age
This is a phase 3 randomized, modified double-blind study whose purpose is to measure whether 3 lots of the investigational pneumococcal vaccine PCV21 can help the body to develop germ-fighting agents called "antibodies"…
- Trial name
- NCT07348692
- Testing
- PCV21 vaccine, 20vPCV licensed vaccine
- Where
- 25 sites in United States, Honduras and 2 more
- Volunteers
- 2,195 people, healthy volunteers welcome
- Sponsor
- Sanofi
Pneumococcal Infection
A Clinical Study of Novel Pneumococcal Vaccine V118C in Children (V118C-002)
Researchers are looking for new vaccines to prevent pneumococcal disease, which is any infection in the lungs or other parts of the body that is caused by a type of bacteria called Streptococcus pneumoniae.
- Trial name
- NCT07300267
- Testing
- V118C (Stage 1), V118C (Stage 2), PCV20 (Stage 1)
- Where
- 15 sites in United States
- Volunteers
- 210 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Pneumococcal Disease
A Study to Learn About the Safety and Immune Response of a New Pneumococcal Vaccine in Adults
The purpose of this study is to learn about the safety and immune effects of a pneumococcal vaccine in adults. This vaccine can possibly provide protection against further pneumococcal disease.
- Trial name
- NCT06182124
- Testing
- Multivalent Pneumococcal Vaccine - Formulation 1, Multivalent Pneumococcal Vaccine - Formulation 2, 20-valent pneumococcal conjugate vaccine (20vPnC)
- Where
- 20 sites in United States
- Volunteers
- 1,710 people, healthy volunteers welcome
- Sponsor
- Pfizer
Pneumococcal Infections
Study Evaluating 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants in India
The purpose of this study is to assess the safety, tolerability and immunogenicity of a 13-valent pneumococcal conjugate vaccine (13vPnC) compared to Prevenar (7vPnC), when given concomitantly with routine paediatric vaccinations…
- Trial name
- NCT00452790
- Testing
- 13-valent Pneumococcal Conjugate Vaccine, 7 valent pneumococcal conjugate vaccine
- Where
- 12 sites in India
- Volunteers
- 708 people, healthy volunteers welcome
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Vaccine, Pneumococcal Disease
Induction of Cross-protective Antibodies for Serogroup 33 by Pneumococcal Conjugate Vaccines
The goal of this study is to learn whether different types of vaccines to prevent bacterial infections are able to effectively create antibodies that defend against certain types of bacteria.
- Trial name
- Group 33/PCVs (NCT07135453)
- Testing
- Pneumococcal Vaccine
- Where
- United States
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- University of Alabama at Birmingham
Pneumococcal Infectious Disease
Phase I Clinical Trial of PCV24 in Children Aged 2 Months (Minimum 6 Weeks) to 17 Years
Phase I clinical trial of 24-valent pneumococcal conjugate vaccine (PCV24) developed by Shanghai Reinovax Biologics Co., LTD will be conducted in children aged 2 Months (Minimum 6 Weeks) to 17 Years .
- Trial name
- NCT06675032
- Testing
- PCV24 formulation 1, PCV24 formulation 2, 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine
- Where
- China
- Volunteers
- 230 people, healthy volunteers welcome
- Sponsor
- Reinovax Biologics Co., LTD
Pneumococcal Infectious Disease
Phase II Clinical Trial of 24-valent Pneumococcal Polysaccharide Conjugate Vaccine
A phase II clinical trial of a 24-valent pneumococcal conjugate vaccine (PCV24) developed by Shanghai Reinovax Biologics Co., LTD will be conducted in Chinese adults aged 18 years and older.
- Trial name
- NCT06678620
- Testing
- Reinovax PCV24 formulation 1, Reinovax PCV24 formulation 2, Reinovax PCV24 formulation 3
- Where
- 2 sites in China
- Volunteers
- 992 people, healthy volunteers welcome
- Sponsor
- Reinovax Biologics Co., LTD
Pneumococcal Diseases
A Study to Evaluate 20vPnC in Healthy Chinese Infants
The purpose of this study is to evaluate a study vaccine called 20-valent pneumococcal conjugate vaccine (20vPnC). The study will assess whether the study vaccine is safe to use in healthy infants.
- Trial name
- NCT07754539
- Testing
- 20vPnC, 13vPnC
- Where
- 4 sites in China
- Volunteers
- 1,250 people, healthy volunteers welcome
- Sponsor
- Pfizer
Pneumococcal Infections, Streptococcal Infections
A Study to Evaluate the Immunogenicity and Safety of 13-valent Pneumococcal Conjugate Vaccine (PCV13i) in Healthy Infants Aged 2 Months (Minimum 6 Weeks)
This is a Phase 3 randomized, observation-blinded, active-controlled, parallel-group clinical trial designed to evaluate the immunogenicity, safety, and functional antibody response of the experimental vaccine versus the control…
- Conditions
- Pneumococcal Infections, Streptococcal Infections, Bacterial Infections
- Trial name
- NCT07017777
- Testing
- PCV13i, Prevnar 13
- Where
- 3 sites in Thailand
- Volunteers
- 600 people, healthy volunteers welcome
- Sponsor
- CanSino Biologics Inc.
Streptococcus Pneumoniae Infection
Clinical Trial of the 24-valent Pneumococcal Polysaccharide Conjugate Vaccine (CRM197/Tetanus Toxoid)
This clinical trial consists of Phase I and Phase II. The objective is to evaluate the safety and immunogenicity of the 24-valent pneumococcal polysaccharide conjugate vaccine (CRM197/tetanus toxoid) in individuals aged 2 months…
- Trial name
- NCT07600983
- Testing
- 24-valent pneumococcal polysaccharide conjugate vaccine (CRM197/tetanus toxoid) (referred to as PCV24) (dose M), PCV24 vaccine (dose H), PCV24 vaccine (dose M)
- Where
- 2 sites in China
- Volunteers
- 854 people, healthy volunteers welcome
- Sponsor
- CanSino Biologics Inc.
Pneumococcal Infections, Streptococcal Infections
A Clinical Trial of the 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (CRM197/Tetanus Toxoid)
This clinical study will enroll 100 participants from the 2-month-old (minimum 6 weeks) group who previously participated in the Phase III clinical trial of the 13-valent pneumococcal polysaccharide conjugate vaccine (CRM197, TT…
- Conditions
- Pneumococcal Infections, Streptococcal Infections, Bacterial Infections
- Trial name
- NCT07648641
- Testing
- Previously vaccinated with PCV13 (CanSino), Previously vaccinated with PCV13 (Pfizer)
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- CanSino Biologics Inc.